Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002428 · ClinicalTrials.gov registry record · Phase 3
A Comparison of PF708 and Forteo in Osteoporosis Patients
A Phase 3 study of Osteoporosis, sponsored by Pfenex.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
- 20
- Study locations
NCT03002428: Completed Phase 3 study of Osteoporosis, sponsored by Pfenex.
NCT03002428 is a Phase 3 study of Osteoporosis that has completed, run by Pfenex. The registered enrollment target is 181 participants, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002428, a Phase 3 study of Osteoporosis, has completed, sponsored by Pfenex.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.
Conditions Studied
Interventions
- DRUG Teriparatide (PF708)
- DRUG Teriparatide (Forteo)
Study Locations (20)
Arizona
- Radiant Research - Chandler
- Radiant Research - Mesa
- SunValley Arthritis Center - Peoria
- Radiant Research - Phoenix
Alabama
- Radiant Research - Birmingham
- The Orthopaedic Group - Mobile
Nevada
- Radiant Research - Henderson
- Radiant Research - Las Vegas
Ohio
- Radiant Research - Akron
- Radiant Research - Cincinnati
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
- Pennsylvania Regional Center for Arthritis & Osteoporosis Research - Wyomissing
Colorado
- Radiant Research - Colorado Springs
Florida
- OB-GYN Associates of Mid-Florida - Leesburg
Georgia
- Atlanta Research Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-05 |
| Phase | Phase 3 |
What the finished NCT03002428 record still lists
NCT03002428 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 84 other Osteoporosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Teriparatide (PF708) is the first listed.
NCT03002428 names 20 study sites across 13 states, led by Arizona, Alabama, Nevada.
Frequently Asked Questions
What is clinical trial NCT03002428 about?
NCT03002428 is a clinical study titled "A Comparison of PF708 and Forteo in Osteoporosis Patients". The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.
What is the current status of trial NCT03002428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2016-12. Estimated completion is 2018-05.
What conditions does trial NCT03002428 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT03002428?
The interventions under investigation include: Teriparatide (PF708) (DRUG), Teriparatide (Forteo) (DRUG).
Who is sponsoring clinical trial NCT03002428?
This trial is sponsored by Pfenex, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03002428 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03002428's enrollment target sits among peer trials
181 33rd of 84 higher than 52 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
COMPLETED · Phase 3
-
Secondary Prevention of Osteoporosis
COMPLETED · Phase 3
-
HORIZON-PFT: Pivotal Fracture Trial
COMPLETED · Phase 3
-
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia